Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Rapid Review
| Commenced | Completed | Outcome |
| 31/05/2016 | 14/06/2016 | Full Pharmacoeconomic Evaluation Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 27/10/2016 | 13/03/2017 | The cost effectiveness of daratumumab (Darzalex®) monotherapy has not been demonstrated. Therefore it is not recommended for reimbursement. |
The HSE has approved reimbursement following confidential price negotiations; April 2018.